-
公开(公告)号：US08905979B2
公开(公告)日：2014-12-09
申请号：US13252532
申请日：2011-10-04
申请人： Egbert Herting , Wolfgang Gopel , Paolo Chiesi
发明人： Egbert Herting , Wolfgang Gopel , Paolo Chiesi
CPC分类号： A61K9/0082 , A61K38/395
摘要： The present invention concerns a method for treating a respiratory distress in a infant in need of such treatment, the method comprising intratracheal administration of a pulmonary surfactant by a thin tube.The invention also concerns a kit for performing said method.
摘要翻译： 本发明涉及一种治疗需要这种治疗的婴儿的呼吸窘迫的方法，该方法包括通过细管气管内给予肺表面活性剂。 本发明还涉及用于执行所述方法的套件。
-
2.发明申请公开(公告)号：US20110130333A1
公开(公告)日：2011-06-02
申请号：US12786845
申请日：2010-05-25
申请人： Massimo GIOSSI , Roberta Razzetti , Paolo Chiesi
发明人： Massimo GIOSSI , Roberta Razzetti , Paolo Chiesi
CPC分类号： A61K31/573 , A61K35/42 , A61K45/06 , A61K2300/00
摘要： Administration of a modified natural surfactant in combination with a corticosteroid is effective for the prevention of bronchopulmonary dysplasia (BPD) and lowers the markers of pulmonary oxidative stress.
摘要翻译： 施用改性天然表面活性剂与皮质类固醇相结合可有效预防支气管肺发育不良（BPD），降低肺部氧化应激标志物。
-
3.发明申请公开(公告)号：US20100047184A1
公开(公告)日：2010-02-25
申请号：US12605558
申请日：2009-10-26
CPC分类号： A61K9/0007
摘要： A pharmaceutical composition in the form of effervescent tablets comprising an active ingredient and an effervescent blend, comprising an acidic component and sodium glycine carbonate as alkaline components. Preferred acid components are fumaric acid, maleic acid, and their salts. Tablets are prepared in normal thermohygrometric conditions and with standard tabletting equipment. A pre-granulation process is also disclosed.
摘要翻译： 泡腾片形式的药物组合物，其包含活性成分和泡腾混合物，其包含酸性组分和作为碱性组分的甘氨酸钠。 优选的酸组分是富马酸，马来酸及其盐。 在正常的温湿度条件和标准压片设备中制备片剂。 还公开了预制粒工艺。
-
公开(公告)号：US06967017B1
公开(公告)日：2005-11-22
申请号：US10030101
申请日：2000-07-20
CPC分类号： A61K9/0078 , A61K31/58
摘要： The present invention relates to optimized formulations of antiinflammatory steroids for nebulisation and a process for the preparation thereof. More particularly, the invention relates to formulations for monodose or multidose vials in the form of preservative-free stable solutions of a more acceptable osmolarity, which can effectively be nebulised with the nebulisers currently available on the market and are well-tolerated by patients.
摘要翻译： 本发明涉及用于雾化的抗炎类固醇的优化制剂及其制备方法。 更具体地说，本发明涉及具有更可接受的渗透压的无防腐剂稳定溶液形式的单糖或多剂量小瓶的制剂，其可以有效地与目前市场上可获得的喷雾器雾化并且被患者良好耐受。
-
5.发明授权Carrier mixed with additives having lubricant properties for preparing powdery pharmaceutical compositions for inhalation 有权载体与具有用于制备用于吸入的粉末状药物组合物的润滑剂性质的添加剂混合公开(公告)号：US06528096B1
公开(公告)日：2003-03-04
申请号：US09603620
申请日：2000-06-26
申请人： Rossella Musa , Paolo Ventura , Paolo Chiesi
发明人： Rossella Musa , Paolo Ventura , Paolo Chiesi
IPC分类号： A61K916
CPC分类号： A61K9/0075 , A61K9/1647 , A61K31/00 , A61K31/203 , A61K31/231 , A61K31/232 , A61K47/26 , C07C45/00 , C07C45/29 , C07C45/298 , C07C45/71 , C07C47/47 , C07C59/64 , C07C59/72 , C07C69/734 , C07C47/277 , C07C49/84 , C07C47/575
摘要： Powdery pharmaceutical compositions including an active ingredient and carrier particles containing only a small amount of lubricant, 0.1-0.5% by weight, are used to prepare dry powder inhalers in order to increase the fine particle dose. A process for coating the surface of the carrier particles with such little amount of lubricant is also provided. Use of limited amount of lubricant is safe and provides ordered stable mixtures without segregation of the active particles during handling and before use.
摘要翻译： 使用包含活性成分和仅含少量0.1-0.5重量％润滑剂的载体颗粒的粉末药物组合物来制备干粉吸入器以增加细粒剂量。 还提供了用少量润滑剂涂覆载体颗粒表面的方法。 使用有限量的润滑剂是安全的，并提供有序的稳定混合物，而不会在处理和使用前分离活性颗粒。
-
6.发明授权Process for the preparation of suspensions of drug particles for inhalation delivery 有权用于制备用于吸入输送的药物颗粒的悬浮液的方法公开(公告)号：US06464958B1
公开(公告)日：2002-10-15
申请号：US09830884
申请日：2001-05-22
IPC分类号： A61K912
CPC分类号： A61K9/0078 , A61K31/573 , Y10S977/904 , Y10S977/906 , Y10S977/926
摘要： The invention is directed to a process for the preparation of suspensions of drug particles for inhalation delivery, said process providing particles of optimized particle size and distribution homogeneously dispersed in the carrier. The process, which is also suitable for the preparation of sterile suspensions, includes the step of homogenizing and micronizing the formulation in a turboemulsifier provided with a high-potency turbine, optionally followed by a treatment in a high-pressure homogenizer. A further aspect of the invention is directed to a process for preparing micronized sterile beclomethasone dipropionate by gamma-irradiation.
摘要翻译： 本发明涉及用于制备用于吸入输送的药物颗粒的悬浮液的方法，所述方法提供均匀分散在载体中的优化粒径和分布的颗粒。 也适用于制备无菌悬浮液的方法包括在具有高效率涡轮机的涡轮乳化器中均化和微粉化制剂的步骤，任选地随后在高压均化器中进行处理。 本发明的另一方面涉及通过γ-照射制备微粉化无色倍氯米松二丙酸酯的方法。
-
7.发明授权
公开(公告)号：US5936125A
公开(公告)日：1999-08-10
申请号：US962706
申请日：1997-11-03
申请人： Paolo Chiesi , Paolo Ventura , Vittorino Servadio , Maurizio Del Canale , Renato De Fanti , Gabriele Amari
发明人： Paolo Chiesi , Paolo Ventura , Vittorino Servadio , Maurizio Del Canale , Renato De Fanti , Gabriele Amari
IPC分类号： C07B53/00 , C07B61/00 , C07C213/00 , C07C213/02 , C07C215/64 , C07C217/74 , C07C211/00
CPC分类号： C07C213/02 , C07C2102/10
摘要： A process, and variations thereof, for the preparation of 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalene derivatives of formula (I), wherein R.sub.1, R.sub.2, R.sub.3 can independently be hydrogen or lower alkyl.
-
8.发明授权Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin 失效含有碱式药物，酸和环糊精的高溶解性多组分包合配合物
公开(公告)号：US5855916A
公开(公告)日：1999-01-05
申请号：US418519
申请日：1995-11-15
申请人： Paolo Chiesi , Paolo Ventura , Massimo Pasini , Josef Szejtli , Maria Vikmon , Enrico Redenti
发明人： Paolo Chiesi , Paolo Ventura , Massimo Pasini , Josef Szejtli , Maria Vikmon , Enrico Redenti
CPC分类号： B82Y5/00 , A61K47/48969
摘要： A multicomponent inclusion complex of a basic drug, an acid and a cyclodextrin has enhanced water-solubility.
摘要翻译： PCT No.PCT / EP94 / 00205 Sec。 371日期：1995年11月15日 102（e）日期1995年11月15日PCT 1994年1月26日PCT PCT。 公开号WO94 / 16733 日期1994年8月4日碱性药物，酸和环糊精的多组分包合物具有增强的水溶性。
-
9.发明授权Valproic and (E)-2-valproenoic acid derivatives, and pharmaceutical compositions therefrom 失效VALPROIC和（E）-2-巯基酸衍生物及其药物组合物
公开(公告)号：US5162573A
公开(公告)日：1992-11-10
申请号：US63643
申请日：1987-06-17
申请人： Paolo Chiesi , Vittorino Servadio , Flavio Villani
发明人： Paolo Chiesi , Vittorino Servadio , Flavio Villani
IPC分类号： C07D307/89 , A61K31/22 , A61K31/235 , A61K31/335 , A61K31/34 , A61K31/343 , A61K31/357 , A61K31/40 , A61K31/4015 , A61K31/44 , A61K31/4402 , A61K31/4418 , A61P25/08 , C07C69/02 , C07C69/28 , C07C69/533 , C07C69/618 , C07C69/78 , C07C69/96 , C07D207/40 , C07D207/404 , C07D213/30 , C07D317/30 , C07D317/34 , C07D317/36 , C07D317/40
CPC分类号： C07D207/404 , C07D213/30 , C07D317/40
摘要： 2-Propyl-2-pentanoic acid (valproic acid) esters and (E)-2-propyl-2-pentenoic acid [(E)-2-valproenoic acid] esters surprisingly proved to have valuable properties, in that they show anticonvulsive and antiepileptic activities comparable with those of valproic acid, as well as an improved bioavailability and a markedly reduced toxicity.
摘要翻译： 2-丙基-2-戊酸（丙戊酸）酯和（E）-2-丙基-2-戊烯酸[（E）-2-戊烯酸]酯令人惊奇地证明具有有价值的性质，因为它们显示抗惊厥和 抗癫痫活动与丙戊酸的相似，以及改善的生物利用度和显着降低的毒性。
-
10.发明授权2-amino-1,2,3,4-tetrahydronaphthalene derivatives with cardiovascular activity, process for their preparation and pharmaceutical compositions containing them 失效具有心血管活性的2-氨基-1,2,3,4-四氢萘并噻吩衍生物，其制备方法和含有它们的药物组合物
公开(公告)号：US5096929A
公开(公告)日：1992-03-17
申请号：US544201
申请日：1990-06-26
IPC分类号： A61K31/135 , A61P9/04 , A61P9/08 , C07C213/02 , C07C217/74
CPC分类号： C07C217/74 , C07C2102/10
摘要： 5,6-Dimethoxy-2-[2-(4-hydroxyphenyl)-2-hydroxy-2-methylethyl]amino- 1,2,3,4-tetrahydronaphthalene has inotropic and vasodilating activities and therefore can be used in the treatment of cardiocirculatory failure. The compound can be in the form of a single stereoisomer or as a mixture of two or more stereoisomers.
-
-
-
-
-
-
-
-
-
搜索结果
48 条记录 (耗时 0.019 秒)
